Reslizumab

Reslizumab
Mass / length primary structure	146.8  kDa
Identifier
External IDs	CAS number : 241473-69-8
Drug information
ATC code	R03 DX08
Drug class	Monoclonal antibody

Reslizumab (trade name: Cinqaero by Teva Pharmaceutical Industries ) is a humanized monoclonal antibody used to treat bronchial asthma . Reslizumab binds specifically to human interleukin-5 (IL-5) and interferes with the binding of IL-5 to its cell surface receptor.

indication

In the European Union , reslizumab is approved as an add-on therapy in adult patients with severe eosinophilic asthma, which is inadequately controlled despite high-dose inhaled corticosteroids plus another maintenance drug.

Mechanism of action

In eosinophilic asthma, symptoms are associated with an excess of a certain type of white blood cell ( eosinophil ) in the blood and lungs. Reslizumab is a monoclonal antibody that binds specifically to interleukin-5, which stimulates the growth and activity of eosinophils. By attaching to interleukin-5 and blocking its activity, reslizumab reduces the number of eosinophils in the blood and lungs. This will reduce inflammation, which will reduce asthma attacks and improve symptoms.

Side effects

The most common side effect is an increase in creatine phosphokinase in the blood (around 2% of patients in the clinical trials). Anaphylactic reactions occurred in less than 1% of patients.

Individual evidence

1. ↑ technical information Cinqaero. European Medicines Agency, accessed December 25, 2017 . 
2. ↑ Summary of the EPAR for the public. European Medicines Agency, accessed December 25, 2017 . 

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !